[
  {
    "ts": "2026-02-03T02:10:09+00:00",
    "headline": "ERLEADA And DARZALEX FASPRO Updates Shape Johnson And Johnson Oncology Story",
    "summary": "New clinical data supports ERLEADA for metastatic castration sensitive prostate cancer, reinforcing its role in current treatment practice. DARZALEX FASPRO received expanded FDA approval for newly diagnosed multiple myeloma patients who are not eligible for stem cell transplant. These updates reflect further development in Johnson & Johnson's oncology portfolio under ticker NYSE:JNJ. For investors tracking NYSE:JNJ, these oncology updates come as the stock trades around $230.75, with a...",
    "url": "https://finance.yahoo.com/news/erleada-darzalex-faspro-updates-shape-021009894.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "72430741-6f88-3672-9ddf-32d797d2f9d5",
      "content": {
        "id": "72430741-6f88-3672-9ddf-32d797d2f9d5",
        "contentType": "STORY",
        "title": "ERLEADA And DARZALEX FASPRO Updates Shape Johnson And Johnson Oncology Story",
        "description": "",
        "summary": "New clinical data supports ERLEADA for metastatic castration sensitive prostate cancer, reinforcing its role in current treatment practice. DARZALEX FASPRO received expanded FDA approval for newly diagnosed multiple myeloma patients who are not eligible for stem cell transplant. These updates reflect further development in Johnson & Johnson's oncology portfolio under ticker NYSE:JNJ. For investors tracking NYSE:JNJ, these oncology updates come as the stock trades around $230.75, with a...",
        "pubDate": "2026-02-03T02:10:09Z",
        "displayTime": "2026-02-03T02:10:09Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VmOStVnJjLnU3xikg4stLA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/trESudVvS0UypUeXuQ_Yww--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/erleada-darzalex-faspro-updates-shape-021009894.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/erleada-darzalex-faspro-updates-shape-021009894.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-03T09:34:16+00:00",
    "headline": "BofA Lifts PT on Johnson & Johnson (JNJ) to $227 From $221 – Here’s Why",
    "summary": "Johnson & Johnson (NYSE:JNJ) is one of the best long term low volatility stocks to invest in. On January 30, BofA lifted the price target on Johnson & Johnson (NYSE:JNJ) to $227 from $221 while maintaining a Neutral rating on the shares. The firm told investors that the increased price target points towards a higher […]",
    "url": "https://finance.yahoo.com/news/bofa-lifts-pt-johnson-johnson-093416862.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "341681ef-898c-30f9-8eb0-39b22964e649",
      "content": {
        "id": "341681ef-898c-30f9-8eb0-39b22964e649",
        "contentType": "STORY",
        "title": "BofA Lifts PT on Johnson & Johnson (JNJ) to $227 From $221 – Here’s Why",
        "description": "",
        "summary": "Johnson & Johnson (NYSE:JNJ) is one of the best long term low volatility stocks to invest in. On January 30, BofA lifted the price target on Johnson & Johnson (NYSE:JNJ) to $227 from $221 while maintaining a Neutral rating on the shares. The firm told investors that the increased price target points towards a higher […]",
        "pubDate": "2026-02-03T09:34:16Z",
        "displayTime": "2026-02-03T09:34:16Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/f9ccf3c88c7274582ef19e20143427c2",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "CAPLYTA Shows Stronger Remission Results in Phase 3 MDD Data, JNJ Says",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qG_90ptmVmYmlFzMjoC0Yw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/f9ccf3c88c7274582ef19e20143427c2.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Q3JcjOP_BI3o_9_ANEkK.w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/f9ccf3c88c7274582ef19e20143427c2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bofa-lifts-pt-johnson-johnson-093416862.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bofa-lifts-pt-johnson-johnson-093416862.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "BAC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-03T11:59:00+00:00",
    "headline": "Bristol Myers Squibb Introduces \"Change the Target. Change What’s Possible.\" to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care",
    "summary": "PRINCETON, N.J., February 03, 2026--Bristol Myers Squibb Introduces \"Change the Target. Change What’s Possible.\" to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care",
    "url": "https://finance.yahoo.com/news/bristol-myers-squibb-introduces-change-115900219.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "7329ff0e-7f73-3aa8-b7cd-e1cd99f850dc",
      "content": {
        "id": "7329ff0e-7f73-3aa8-b7cd-e1cd99f850dc",
        "contentType": "STORY",
        "title": "Bristol Myers Squibb Introduces \"Change the Target. Change What’s Possible.\" to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care",
        "description": "",
        "summary": "PRINCETON, N.J., February 03, 2026--Bristol Myers Squibb Introduces \"Change the Target. Change What’s Possible.\" to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care",
        "pubDate": "2026-02-03T11:59:00Z",
        "displayTime": "2026-02-03T11:59:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/facdbec908ef0d232f2abce37c9da87e",
          "originalWidth": 1497,
          "originalHeight": 206,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kZJzRGmsRkiNRUO8k0yWYg--~B/aD0yMDY7dz0xNDk3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/facdbec908ef0d232f2abce37c9da87e.cf.webp",
              "width": 1497,
              "height": 206,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vGFrNCFSq7crKUwNRODMQg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/facdbec908ef0d232f2abce37c9da87e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-introduces-change-115900219.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-introduces-change-115900219.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]